From Wikipedia, the free encyclopedia - View original article
|Non-small-cell lung carcinoma|
|Classification and external resources|
|Non-small-cell lung carcinoma|
|Classification and external resources|
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy is increasingly being used both pre-operatively (neoadjuvant chemotherapy) and post-operatively (adjuvant chemotherapy).
The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants and as mixed cell-type combinations.
Sometimes the phrase "non-small-cell lung cancer" ("not otherwise specified", or NOS) is used generically, usually when a more specific diagnosis cannot be made. This is most often the case when a pathologist examines a small amount of malignant cells or tissue in a cytology or biopsy specimen.
Lung cancer in never-smokers is almost universally NSCLC, with a sizeable majority being adenocarcinoma.
On relatively rare occasions, malignant lung tumors are found to contain components of both SCLC and NSCLC. In these cases, the tumors should be classified as combined small cell lung carcinoma (c-SCLC), and are (usually) treated like "pure" SCLC.
Adenocarcinoma of the lung is currently the most common type of lung cancer in "never smokers" (lifelong non-smokers). Adenocarcinomas account for approximately 40% of lung cancers. Historically, adenocarcinoma was more often seen peripherally in the lungs than small cell lung cancer and squamous cell lung cancer, both of which tended to be more often centrally located. Interestingly, however, recent studies suggest that the "ratio of centrally-to-peripherally occurring" lesions may be converging toward unity for both adenocarcinoma and squamous cell carcinoma.
Squamous cell carcinoma (SCC) of the lung is more common in men than in women. It is closely correlated with a history of tobacco smoking, more so than most other types of lung cancer. According to the Nurses' Health Study, the relative risk of SCC is approximately 5.5, both among those with a previous duration of smoking of 1 to 20 years, and those with 20 to 30 years, compared to never-smokers. The relative risk increases to approximately 16 with a previous smoking duration of 30 to 40 years, and approximately 22 with more than 40 years.
Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed epithelial cells in the lung. LCLC's have typically comprised between around 10% of all NSCLC in the past, although newer diagnostic techniques seem to be reducing the incidence of diagnosis of "classic" LCLC in favor of more poorly differentiated squamous cell carcinomas and adenocarcinomas. LCLC is, in effect, a "diagnosis of exclusion", in that the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. LCLC is differentiated from small cell lung carcinoma (SCLC) primarily by the larger size of the anaplastic cells, a higher cytoplasmic-to-nuclear size ratio, and a lack of "salt-and-pepper" chromatin.
The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) recommend TNM staging, using a uniform scheme for non-small cell lung carcinoma, small-cell lung carcinoma and broncho-pulmonary carcinoid tumors. AJCC has provided an accessible poster version of these copyrighted TNM descriptors to which readers are directed. Extensive presentation of prognostic data for both 6th and 7th edition individual TNM descriptors and overall groups is available.
More than one kind of treatment is often used, depending on the stage of the cancer, the individual's overall health, age, response to chemotherapy, and other factors such as the likely side effects of the treatment.
NSCLCs are usually not very sensitive to chemotherapy and/or radiation, so surgery is the treatment of choice if diagnosed at an early stage, often with adjuvant (ancillary) chemotherapy involving cisplatin. Other treatment choices are chemotherapy, radiation therapy (radiotherapy), and targeted therapy.
New methods of giving radiation treatment allow doctors to be more accurate in treating lung cancers. This means less radiation affects nearby healthy tissues. New methods include Cyberknife and stereotactic radiosurgery (SRS).
A wide variety of chemotherapies are used in advanced (metastatic) NSCLC. Some patients with particular mutations in the EGFR gene respond to EGFR tyrosine kinase inhibitors such as gefitinib.
|Company Name||Product Names||Description||Partners||Latest Stage of Development|
|Transgene S.A.||TG4010 (Compound #), MVA-MUC1-IL2 (Informal)||Recombinant Modified Vaccinia Ankara (MVA) virus vector encoding the mucin 1 (MUC1; CD227) tumor-associated antigen and IL-2||Novartis||Phase II/III|
|Amgen Inc.||AMG 706 (Compound #), motesanib diphosphate (Generic)||Small molecule antagonist of VEGF receptors 1, 2 and 3, platelet derived growth factor receptor (PDGFR) and c-Kit||Takeda Pharmaceutical Co. Ltd.||Phase III|
|Amgen Inc.||Aranesp (Brand), Nesp (Brand), Nespo (Brand), KRN321 (Compound #), darbepoetin alfa (Generic), Aranesp (Informal), NESP (Other), novel erythropoiesis stimulating protein (NESP) (Other)||Erythropoiesis stimulating protein||Phase III|
|ArQule Inc.||ARQ 197 (Compound #), tivantinib (Generic)||Small molecule inhibitor of c-Met receptor tyrosine kinase||Daiichi Sankyo Co. Ltd.; Kyowa Hakko Kirin Co. Ltd.||Phase III|
|Chong Kun Dang Pharmaceutical Corp.||CKD-602 (Compound #), belotecan (Generic), Camtobell (Informal)||Camptothecin analogue||Phase III|
|Eisai Co. Ltd.||Halaven (Brand), E7389 (Compound #), eribulin mesylate (Generic), Halaven (Other)||Synthetic analog of halichondrin B||Phase III|
|Eli Lilly and Co.||IMC-1121B (Compound #), LY3009806 (Compound #), ramucirumab (Generic)||Human IgG1 mAb VEGFR-2 antagonist||Phase III|
|Eli Lilly and Co.||IMC-11F8 (Compound #), LY3012211 (Compound #), necitumumab (Generic)||Human IgG1 mAb against EGFR||Bristol-Myers Squibb Co.||Phase III|
|GlaxoSmithKline plc||GSK1572932A (Compound #), Lung cancer vaccine (Informal), MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) (Other)||Cancer vaccine against MAGE-A3 antigen||Phase III|
|OncoGenex Pharmaceuticals Inc.||OGX-011 (Compound #), TV-1011 (Compound #), custirsen sodium (Generic)||Second-generation antisense inhibitor of serum clusterin mRNA||Isis Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.||Phase III|
|Oncothyreon Inc.||Stimuvax (Former), BLP25 liposome vaccine (Other), L-BLP25 (Other)||Liposomal vaccine containing a synthetic 25 amino acid peptide sequence from mucin 1 (MUC1; CD227)||Merck KGaA; Ono Pharmaceutical Co. Ltd.||Phase III|
|Ono Pharmaceutical Co. Ltd.||BMS-936558 (Compound #), MDX-1106 (Compound #), ONO-4538 (Compound #), nivolumab (Other)||Human mAb against PD-1 receptor (PDCD1; PD-1; CD279)||Bristol-Myers Squibb Co.||Phase III|
|Ono Pharmaceutical Co. Ltd.||EMD531444 (Compound #), ONO-7165 (Compound #)||Peptide vaccine targeting polymorphic epithelial mucin (PEM; MUC-1)||Merck KGaA||Phase III|
|Pfizer Inc.||PF-00299804 (Compound #), dacomitinib (Generic)||Inhibitor of human EGFR1, EGFR2 and EGFR4||SFJ Pharmaceuticals Inc.||Phase III|
|Synta Pharmaceuticals Corp.||STA-9090 (Former compound #), ganetespib (Generic)||Small molecule heat shock protein 90 (Hsp90) inhibitor||Phase III|
|Eli Lilly and Co.||pemetrexed||PARAMOUNT trial||none||Phase III|